Ergoteles’s Health Catalyst HCAT Stock Holding History

Ergoteles’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12,049	Closed	-$151K	–	391
2023 Q2	$151K	Buy	+12,049	New	+$144K	0.01%	884
2022 Q2	–	Sell	-24,338	Closed	-$636K	–	1791
2022 Q1	$636K	Buy	+24,338	New	+$691K	0.02%	582

Other funds holding HCAT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Daventry Group New York $133M AUM 32.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ergoteles's HCAT Position: Q3 2023 in Review

Ergoteles sold out of Health Catalyst (HCAT) in Q3 2023, closing a stake of 12,049 shares — an estimated $151K sold.

Ergoteles first reported a position in HCAT in Q1 2022 and held it in 2 quarters. The position peaked at $636K in Q1 2022. 159 funds tracked by Wall St. Rank hold HCAT as of Q3 2023.

Ergoteles reported no remaining Health Catalyst position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 12,049 Health Catalyst shares in Q3 2023, an estimated $151K.
Ergoteles first reported a position in Health Catalyst in Q1 2022 and held it in 2 quarters.
Ergoteles's Health Catalyst position peaked at $636K in Q1 2022.
159 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.